Angiogenesis as a therapeutic target

[1]  Kentaro Takahashi,et al.  [Von Hippel-Lindau disease]. , 2006, Nihon rinsho. Japanese journal of clinical medicine.

[2]  Greg Yothers,et al.  Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. , 2005, The New England journal of medicine.

[3]  C. Lewis,et al.  Macrophage responses to hypoxia: implications for tumor progression and anti-cancer therapies. , 2005, The American journal of pathology.

[4]  M. Klagsbrun,et al.  A role for axon guidance receptors and ligands in blood vessel development and tumor angiogenesis. , 2005, Cytokine & growth factor reviews.

[5]  L. Ellis,et al.  Vascular endothelial growth factor receptor‐1 promotes migration and invasion in pancreatic carcinoma cell lines , 2005, Cancer.

[6]  P. Carmeliet,et al.  Common mechanisms of nerve and blood vessel wiring , 2005, Nature.

[7]  D. Geddes,et al.  The efficacy of a 'master switch gene' HIF-1alpha in a porcine model of chronic myocardial ischaemia. , 2005, European heart journal.

[8]  Stephen L. Brown,et al.  Vascular targeting therapies for treatment of malignant disease , 2005, Cancer.

[9]  Elena B. Pasquale,et al.  Eph receptor signalling casts a wide net on cell behaviour , 2005, Nature Reviews Molecular Cell Biology.

[10]  I. Tannock,et al.  Repopulation of cancer cells during therapy: an important cause of treatment failure , 2005, Nature Reviews Cancer.

[11]  Danila Coradini,et al.  Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. , 2005, Cancer research.

[12]  E. Pasquale.  Developmental cell biology: Eph receptor signalling casts a wide net on cell behaviour , 2005, Nature Reviews Molecular Cell Biology.

[13]  Dennis C. Sgroi,et al.  Stromal Fibroblasts Present in Invasive Human Breast Carcinomas Promote Tumor Growth and Angiogenesis through Elevated SDF-1/CXCL12 Secretion , 2005, Cell.

[14]  M. Simons.  Angiogenesis: where do we stand now? , 2005, Circulation.

[15]  R. Kalluri,et al.  Function of endogenous inhibitors of angiogenesis as endothelium-specific tumor suppressors. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[16]  B. Teicher,et al.  Combination of Antiangiogenic Therapy With Other Anticancer Therapies: Results, Challenges, and Open Questions , 2005 .

[17]  B. Peters,et al.  Contribution of bone marrow–derived endothelial cells to human tumor vasculature , 2005, Nature Medicine.

[18]  P Kelly Marcom,et al.  Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  Napoleone Ferrara,et al.  Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. , 2005, Cancer research.

[20]  R. Jain.  Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy , 2005, Science.

[21]  Giampietro Gasparini,et al.  Combination of antiangiogenic therapy with other anticancer therapies: results, challenges, and open questions. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  R. D'Amato,et al.  Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis; Implications for cellular surrogate marker analysis of antiangiogenesis. , 2005, Cancer cell.

[23]  E. Gragoudas,et al.  Pegaptanib for neovascular age-related macular degeneration. , 2004, The New England journal of medicine.

[24]  Lei Xu,et al.  Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. , 2004, Cancer cell.

[25]  Dhara N. Amin,et al.  Tumor-Associated Endothelial Cells with Cytogenetic Abnormalities , 2004, Cancer Research.

[26]  Thomas Hartmann,et al.  Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2. , 2004, Cancer cell.

[27]  M. Abe,et al.  Vasohibin as an endothelium-derived negative feedback regulator of angiogenesis. , 2004, The Journal of clinical investigation.

[28]  Wenjun Guo,et al.  Integrin signalling during tumour progression , 2004, Nature Reviews Molecular Cell Biology.

[29]  Napoleone Ferrara,et al.  Vascular endothelial growth factor: basic science and clinical progress. , 2004, Endocrine reviews.

[30]  N. Rioux-Leclercq,et al.  Human endocrine gland-derived vascular endothelial growth factor: expression early in development and in Leydig cell tumors suggests roles in normal and pathological testis angiogenesis. , 2004, The Journal of clinical endocrinology and metabolism.

[31]  D. Yamashiro,et al.  Vascular remodeling and clinical resistance to antiangiogenic cancer therapy. , 2004, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[32]  F. Peale,et al.  VEGF‐null cells require PDGFR α signaling‐mediated stromal fibroblast recruitment for tumorigenesis , 2004, The EMBO journal.

[33]  Oswald Wagner,et al.  Lymphoma-specific genetic aberrations in microvascular endothelial cells in B-cell lymphomas. , 2004, The New England journal of medicine.

[34]  J. Brugarolas,et al.  Dysregulation of HIF and VEGF is a unifying feature of the familial hamartoma syndromes. , 2004, Cancer cell.

[35]  J. Berlin,et al.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.

[36]  David M Jablons,et al.  Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  Robert S. Kerbel,et al.  The anti-angiogenic basis of metronomic chemotherapy , 2004, Nature Reviews Cancer.

[38]  H. Augustin,et al.  Inhibition of tumor growth and angiogenesis by soluble EphB4. , 2004, Neoplasia.

[39]  Kenneth J. Hillan,et al.  Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer , 2004, Nature Reviews Drug Discovery.

[40]  Richard J. Jones,et al.  Cancer stem cells: are we missing the target? , 2004, Journal of the National Cancer Institute.

[41]  P. Dobrzanski,et al.  Antiangiogenic and Antitumor Efficacy of EphA2 Receptor Antagonist , 2004, Cancer Research.

[42]  Ricky T. Tong,et al.  Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer , 2004, Nature Medicine.

[43]  John K Smith,et al.  Emerging roles of targeted small molecule protein-tyrosine kinase inhibitors in cancer therapy. , 2004, Oncology research.

[44]  R. Kerbel,et al.  Possible Mechanisms of Acquired Resistance to Anti-angiogenic Drugs: Implications for the Use of Combination Therapy Approaches , 2004, Cancer and Metastasis Reviews.

[45]  W. Gerald,et al.  Effect of angiogenesis inhibition by Id loss and the contribution of bone-marrow-derived endothelial cells in spontaneous murine tumors. , 2003, Cancer cell.

[46]  R. Kerbel,et al.  Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. , 2003, Cancer research.

[47]  Seth M Steinberg,et al.  A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. , 2003, The New England journal of medicine.

[48]  S. Duan,et al.  Induction of tumor angiogenesis by Slit-Robo signaling and inhibition of cancer growth by blocking Robo activity. , 2003, Cancer cell.

[49]  T. Webb.  Work on breast cancer stem cells raises questions about treatment strategies. , 2003, Journal of the National Cancer Institute.

[50]  L. Naldini,et al.  Targeting exogenous genes to tumor angiogenesis by transplantation of genetically modified hematopoietic stem cells , 2003, Nature Medicine.

[51]  Shahin Rafii,et al.  Therapeutic stem and progenitor cell transplantation for organ vascularization and regeneration , 2003, Nature Medicine.

[52]  N. Ferrara,et al.  The biology of VEGF and its receptors , 2003, Nature Medicine.

[53]  D. Hanahan,et al.  Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. , 2003, The Journal of clinical investigation.

[54]  Brian H Annex,et al.  The VIVA Trial Vascular Endothelial Growth Factor in Ischemia for Vascular Angiogenesis , 2003 .

[55]  W. Kaelin,et al.  HIF hydroxylation and the mammalian oxygen-sensing pathway. , 2003, The Journal of clinical investigation.

[56]  Kenneth J. Hillan,et al.  Angiogenesis-Independent Endothelial Protection of Liver: Role of VEGFR-1 , 2003, Science.

[57]  G. Sledge,et al.  Resistance in the anti-angiogenic era: nay-saying or a word of caution? , 2003, Trends in molecular medicine.

[58]  H. Dvorak.  Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[59]  M. Shibuya,et al.  MMP9 induction by vascular endothelial growth factor receptor-1 is involved in lung-specific metastasis. , 2002, Cancer cell.

[60]  Napoleone Ferrara,et al.  VEGF and the quest for tumour angiogenesis factors , 2002, Nature Reviews Cancer.

[61]  J. Folkman,et al.  Clinical translation of angiogenesis inhibitors , 2002, Nature Reviews Cancer.

[62]  L. Ellis,et al.  Phase I study of recombinant human endostatin in patients with advanced solid tumors. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[63]  G. Yancopoulos,et al.  VEGF-Trap: A VEGF blocker with potent antitumor effects , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[64]  K. Shimada,et al.  Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: a pilot study and a randomised controlled trial , 2002, The Lancet.

[65]  S. Rafii,et al.  Placental growth factor reconstitutes hematopoiesis by recruiting VEGFR1+ stem cells from bone-marrow microenvironment , 2002, Nature Medicine.

[66]  N. Ferrara,et al.  VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism , 2002, Nature.

[67]  R. Lederman,et al.  Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial , 2002, The Lancet.

[68]  S. Rafii,et al.  Recruitment of Stem and Progenitor Cells from the Bone Marrow Niche Requires MMP-9 Mediated Release of Kit-Ligand , 2002, Cell.

[69]  D. Hanahan,et al.  VEGF-A has a critical, nonredundant role in angiogenic switching and pancreatic beta cell carcinogenesis. , 2002, Cancer cell.

[70]  D. Hicklin,et al.  Effect of p53 Status on Tumor Response to Antiangiogenic Therapy , 2002, Science.

[71]  A. Luttun,et al.  Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1 , 2002, Nature Medicine.

[72]  S. Rafii,et al.  Impaired recruitment of bone-marrow–derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth , 2001, Nature Medicine.

[73]  C. Ruhrberg,et al.  Endogenous inhibitors of angiogenesis. , 2001, Journal of cell science.

[74]  Franklin Peale,et al.  Identification of an angiogenic mitogen selective for endocrine gland endothelium , 2001, Nature.

[75]  G. Sledge,et al.  The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors. , 2001, Cancer research.

[76]  D. Eberhard,et al.  Complete inhibition of rhabdomyosarcoma xenograft growth and neovascularization requires blockade of both tumor and host vascular endothelial growth factor. , 2000, Cancer research.

[77]  Stanley J. Wiegand,et al.  Vascular-specific growth factors and blood vessel formation , 2000, Nature.

[78]  Peter Bohlen,et al.  Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity , 2000 .

[79]  J. Mestan,et al.  PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. , 2000, Cancer research.

[80]  J. Folkman,et al.  Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. , 2000, Cancer research.

[81]  S. Baruchel,et al.  Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. , 2000, The Journal of clinical investigation.

[82]  Napoleone Ferrara,et al.  Clinical applications of angiogenic growth factors and their inhibitors , 1999, Nature Medicine.

[83]  A. D. de Vos,et al.  Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen. , 1999, Journal of molecular biology.

[84]  D. Hicklin,et al.  Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. , 1999, Cancer research.

[85]  Haruchika Masuda,et al.  Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization , 1999, Nature Medicine.

[86]  K. Sakaguchi,et al.  Vasostatin, a Calreticulin Fragment, Inhibits Angiogenesis and Suppresses Tumor Growth , 1998, The Journal of experimental medicine.

[87]  Sheela M. Waugh,et al.  2′-Fluoropyrimidine RNA-based Aptamers to the 165-Amino Acid Form of Vascular Endothelial Growth Factor (VEGF165) , 1998, The Journal of Biological Chemistry.

[88]  Shay Soker,et al.  Neuropilin-1 Is Expressed by Endothelial and Tumor Cells as an Isoform-Specific Receptor for Vascular Endothelial Growth Factor , 1998, Cell.

[89]  B R Johansson,et al.  Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. , 1997, Science.

[90]  Thomas N. Sato,et al.  Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. , 1997, Science.

[91]  Takayuki Asahara,et al.  Isolation of Putative Progenitor Endothelial Cells for Angiogenesis , 1997, Science.

[92]  William Arbuthnot Sir Lane,et al.  Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth , 1997, Cell.

[93]  L. DiPietro.  Thrombospondin as a regulator of angiogenesis. , 1997, EXS.

[94]  R. Kerbel,et al.  Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. , 1995, Cancer research.

[95]  A. Pandey,et al.  Role of B61, the ligand for the Eck receptor tyrosine kinase, in TNF-alpha-induced angiogenesis. , 1995, Science.

[96]  A. Ullrich,et al.  Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant , 1994, Nature.

[97]  Bing Li,et al.  Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo , 1993, Nature.

[98]  J. Folkman.  Tumor angiogenesis: therapeutic implications. , 1971, The New England journal of medicine.

[99]  J Folkman,et al.  Transplacental carcinogenesis by stilbestrol. , 1971, The New England journal of medicine.

[100]  K S Mathur,et al.  Vascular diseases. , 1970, The Journal of the Association of Physicians of India.

[101]  H. W. Chalkley,et al.  Vasculae Reactions of Normal and Malignant Tissues in Vivo. I. Vascular Reactions of Mice to Wounds and to Normal and Neoplastic Transplants , 1945 .